Esperion Therapeutics Inc (NAS:ESPR)
$ 2.08 -0.03 (-1.41%) Market Cap: 394.08 Mil Enterprise Value: 445.93 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 54/100

Esperion Therapeutics Inc at JMP Securities Life Sciences Conference Transcript

May 15, 2023 / 06:00PM GMT
Release Date Price: $1.7 (+10.39%)
Jason Butler
JMP Securities - Analyst

Excited to be joined next by Esperion Therapeutics. And with us is Ben Halladay, the company's Chief Financial Officer. It's been an exciting year for Esperion with the presentation of cardiovascular outcomes data for bempedoic acid, which is the company's approved therapy for lowering LDL. Not 100% smooth sailing, as you will talk about with some of your discussions with your partner in Europe.

But I think what's been very, very prominent is the importance of the data, physician's reception to the data, and now already seeing the reaction of prescriptions. So I know am kind of giving a little bit of foreshadowing there, Ben. We just love to get the 30-second overview from you on Esperion and how things are going so far this year.

Ben Halladay
Esperion Therapeutics, Inc. - CFO

Yeah, it's been a great year for us, I know, speed bumps included. We read out our CLEAR Outcomes trial in March 4 at ACC, where we presented the full detail. We had a simultaneous publication in the New England Journal of Medicine. And I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot